MDC CONNECTS 2021
Complex Medicines: 
Ready for the Clinic/Scaling up for Success

22 June 2021  |  2 - 3PM BST

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy

BACKGROUND

The advantages of good formulation - Claire Patterson (SEDA Pharmaceutical Development Services)
Overcoming the challenges of scaling up a complex medicine - Graham Worrall and Emily Port (CPI)
Everything you want to know about development, but were afraid to ask! - Alan Boyd (Boyds)

AGENDA

BOOK YOUR PLACE

ABOUT THE PRESENTERS

OTHER WEBINARS IN THE SERIES

Complex Medicines: A Glance at Novel Drug Delivery Systems
8 June 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Selection and Characterisation of the Lead
18 May 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Understanding Safety & Efficacy
15 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Understanding the Interplay with Biological Systems
25 May 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Why, What, When? Opportunities and Challenges
11 May 2021  |  2 - 3PM BST
Watch the recording >

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

 
Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

And in this final session, a panel of experts will describe how to prepare for the clinic; to formulate, scale up and navigate the regulatory approval process.

Claire Patterson
Claire Patterson is Senior Principal Scientist at Seda Pharmaceutical Development Services Ltd., providing Pharmaceutical Development and Clinical Pharmacology services and consultancy to the Pharma and Biotechnology Industry. She obtained a Master of Pharmacy (MPharm) and a Ph.D. in Pharmaceutics from the Universities of Nottingham and University College London respectively. Claire is an experienced Biopharmaceutics scientist having spent 12 years with former employer AstraZeneca with roles in Early and Late Stage Product Development, linking in vitro to in vivo product performance. Current focus areas include subcutaneous and complex parenteral biopharmaceutics.

Emily Port
Emily Port received a Chemistry MChem from the University of York. Before CPI, and worked in the Formulation team at the Unilever Deodorants Global Design Centre in Leeds, where she developed personal care products to be ready for market. Since joining CPI in 2017, Emily has worked mainly on Nanopharmaceutical projects, with a particular interest in scale up of encapsulation of nucleic acids into lipid nanoparticles.

Prof. Alan Boyd
Professor Alan Boyd,  BSc, MB, ChB, FRSB, FFLM, FRCP, FFPM is a Fellow and immediate Past- President of the Faculty of Pharmaceutical Medicine, UK. A graduate in Biochemistry and Medicine from the University of Birmingham. Following post-graduate training, he joined the pharmaceutical industry at Glaxo and then ICI/Zeneca eventually becoming Global Head of Medical Research for the company. In 1999 he became the R&D Director for Ark Therapeutics Ltd in the UK, specialising in the development of gene therapies.  

In April 2005, he founded Boyd Consultants to support early-stage life-science companies and universities translate research ideas into medicines. Currently works with a wide range of organisations across Europe, North America and Japan.